Early and late extensive chronic graft-versus-host disease in children is characterized by different Th1/Th2 cytokine profiles: findings of the Children's Oncology Group Study ASCT0031.
about
The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host DiseaseThe role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society.Biomarkers in chronic graft-versus-host diseaseNational Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.Glycoprotein YKL-40: a novel biomarker of chronic graft-vs-host disease activity and severity?A combined biomarker and clinical panel for chronic graft versus host disease diagnosisBiologic markers of chronic GVHD.CD56bright natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft-versus-host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results.Biomarkers in chronic graft-versus-host disease: quo vadis?Association of Plasma CD163 Concentration with De Novo-Onset Chronic Graft-versus-Host Disease.Inducible T-Cell Co-Stimulator Impacts Chronic Graft-Versus-Host Disease by Regulating Both Pathogenic and Regulatory T Cells.How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD
P2860
Q28076264-9F0BB5B2-0A77-4E62-A8E2-FD5DFC7BE6ECQ33625948-F50997FB-7A9B-47F5-8106-4ECBCF58ACCAQ35094374-6B8DA855-72C5-4DBC-B12D-7ED6491BADFCQ35533376-A3BD155F-3E52-4F67-AA47-732D0B731768Q37075990-8D9C7734-7375-4202-8429-4FA062963AF4Q37601730-42EF74A1-2770-480E-80E3-87FA1860C8B3Q38123020-7FB6E60A-AA0F-45FB-A423-D25283B532F7Q47123396-708BE8D7-5525-4537-90AB-BBA61DE79BCDQ47713449-49E7C70D-D07B-480C-8B90-50FFF4AAEEC0Q51028682-1C74852B-0DDB-4397-9DCD-5F11516945CDQ55467320-21388D1E-5E39-47D9-803E-B12422493C35Q58782275-B758749B-E240-48C2-A1C9-6AC121B0E88B
P2860
Early and late extensive chronic graft-versus-host disease in children is characterized by different Th1/Th2 cytokine profiles: findings of the Children's Oncology Group Study ASCT0031.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Early and late extensive chron ...... Oncology Group Study ASCT0031.
@ast
Early and late extensive chron ...... Oncology Group Study ASCT0031.
@en
type
label
Early and late extensive chron ...... Oncology Group Study ASCT0031.
@ast
Early and late extensive chron ...... Oncology Group Study ASCT0031.
@en
prefLabel
Early and late extensive chron ...... Oncology Group Study ASCT0031.
@ast
Early and late extensive chron ...... Oncology Group Study ASCT0031.
@en
P2093
P2860
P1476
Early and late extensive chron ...... Oncology Group Study ASCT0031.
@en
P2093
Amina Kariminia
Andrew L Gilman
Frederick D Goldman
Jacob Rozmus
Kirk R Schultz
Kristin Wynne
Mark Krailo
Preeti Satyanarayana
Stephan A Grupp
P2860
P304
P356
10.1016/J.BBMT.2011.05.011
P577
2011-05-25T00:00:00Z